Italian Fine Food Fund Acquires Revi Pharma

Italian Fine Food, a private capital fund managed by AVM sgr spa, has completed the full acquisition of Revi Pharma srl. This strategic move signals the fund's ambition to establish a significant nutraceutical hub within Italy's renowned 'Made in Italy' sector, focusing on an integrated supply chain of high-quality production facilities.

Revi Pharma, headquartered in Milan with its production site in Vernate, specializes in the research, development, and contract manufacturing of dietary supplements, medical devices, and cosmetic products for skincare and haircare. The acquisition aligns with Italian Fine Food's mandate to nurture and enhance regional Italian food and wellness sector excellences.

The Italian nutraceutical market is experiencing robust growth, driven by increasing consumer awareness of health and wellness, and a preference for natural and scientifically backed products. This sector, valued at several billion euros annually, is projected to expand further as preventative healthcare gains prominence. Revi Pharma's established expertise in formulation and manufacturing positions it as a key asset for Italian Fine Food's expansion strategy.

Launched in April 2023 with an initial fundraising target of €100 million, Italian Fine Food has already secured substantial capital commitments, demonstrating strong investor confidence in its specialized investment thesis. The fund's focus on consolidating and scaling businesses within the premium Italian food and wellness segments offers a compelling opportunity for value creation.

This transaction is expected to catalyze the creation of a new integrated nutraceutical platform. By combining Revi Pharma's manufacturing capabilities with potential future acquisitions, Italian Fine Food aims to build a comprehensive value chain, from ingredient sourcing to finished product distribution. Such consolidation is a recognized strategy in private equity to achieve economies of scale and enhance market competitiveness.

The broader implications for the Italian pharmaceutical and cosmetic ingredients sector are significant. This acquisition could encourage further consolidation and investment, fostering innovation and strengthening the competitive position of Italian companies on the global stage. The focus on 'Made in Italy' quality and specialized production is a key differentiator in a crowded international market.